Read More Pharma Industry News GSK to acquire RAPT Therapeutics in strategic push into long-acting food allergy biologics GSK to acquire RAPT Therapeutics for $2.2B, targeting food allergy breakthroughs with ozureprubart. Find out how this changes its immunology strategy. byVenkateshJanuary 21, 2026